Back to search results

Local Anesthetic Concentration for Rebound Pain after Shoulder Surgery

This study is looking at how different concentrations of a local anesthetic (pain-numbing medicine) called bupivacaine affect "rebound pain" (pain that returns after the anesthetic wears off) in patients having shoulder replacement surgery. We are comparing two concentrations of bupivacaine (0.5% and 0.25%) to see if a lower concentration leads to less rebound pain 24 hours after surgery. You might be able to join if you are an adult (18 or older) having total shoulder replacement surgery and do not have certain chronic pain conditions or daily opioid use. The study aims to find out if one concentration is better at managing pain.

Study design
This is a randomized control study, meaning participants are randomly assigned to one of the two bupivacaine groups. The study plans to enroll 168 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your pain will be assessed at 24, 48, and 72 hours after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07146685

Effect of Local Anesthetic Concentration on Rebound Pain

Recruiting
PHASE4Ages 18+InterventionalTreatment
University of Virginia
~10 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:Bupivacaine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Max NRS Pain Score at 24 hours
Measured over 24 hours after intervention

Conditions

Rebound Pain
Shoulder Arthroplasty
Interscalene Block

Explore related trials

Arthroplasty of shoulder

NCT07146685

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UVA Health

    Charlottesville, Virginiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Leon N Grinman, DO · PRINCIPAL_INVESTIGATOR · UVA

Who to contact

Leon N Grinman, DO
[email protected]
434-924-3627
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Total shoulder replacement patients (anatomic and reverse)
Adult patients (greater than or equal to 18 years)
Any gender
Any race

Exclusion

\- Chronic Pain diagnoses including:
substance/opioid use disorder
complex regional pain syndromes
fibromyalgia
Daily persistent opioid use spanning 3 months prior to surgery date
Allergy to local anesthetics or NSAIDS
Respiratory pathologies including:
CPAP- non-compliant / untreated obstructive sleep apnea
COPD
Restrictive lung disease (pulmonary fibrosis, interstitial pneumonia, etc)
Contralateral diaphragm dysfunction
BMI \> 40
Ipsilateral extremity pre-existing nerve injury
GFR \< 60
NSAID contraindications
Inability to follow up
Revision surgery
Patients requesting block as primary (avoidance of general anesthesia)
Need or request for brachial plexus catheter or liposomal bupivacaine
Vulnerable populations (pregnancy, incarceration, etc)
non-English speaking

What this trial measures

  • Max NRS Pain Score at 24 hours24 hours after intervention

    Pain intensity measured using the Numeric Rating Scale (NRS), a 0-10 scale where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate worse pain.